LA JOLLA PHARMACEUTICAL CO (LJPC) Stock Price, Quote, News and Overview
NASDAQ:LJPC - Nasdaq - US5034596040 - Common Stock - Currency: USD
LJPC Quote, Performance and Key Statistics
NASDAQ:LJPC (8/19/2022, 8:00:02 PM)
6.22
0 (0%)
The current stock price of LJPC is 6.22 USD. In the past month the price increased by 0.48%. In the past year, price increased by 68.11%.
LJPC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About LJPC
Company Profile
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
Company Info
LA JOLLA PHARMACEUTICAL CO
201 Jones Road, Suite 400
Waltham MASSACHUSETTS 92121 US
CEO: Larry Edwards
Employees: 61
Company Website: https://www.lajollapharmaceutical.com/
Phone: 16177153600.0
LA JOLLA PHARMACEUTICAL CO / LJPC FAQ
What is the stock price of LA JOLLA PHARMACEUTICAL CO today?
The current stock price of LJPC is 6.22 USD.
What is the ticker symbol for LA JOLLA PHARMACEUTICAL CO stock?
The exchange symbol of LA JOLLA PHARMACEUTICAL CO is LJPC and it is listed on the Nasdaq exchange.
On which exchange is LJPC stock listed?
LJPC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LA JOLLA PHARMACEUTICAL CO stock?
6 analysts have analysed LJPC and the average price target is 6.35 USD. This implies a price increase of 2.16% is expected in the next year compared to the current price of 6.22. Check the LA JOLLA PHARMACEUTICAL CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LA JOLLA PHARMACEUTICAL CO worth?
LA JOLLA PHARMACEUTICAL CO (LJPC) has a market capitalization of 158.96M USD. This makes LJPC a Micro Cap stock.
How many employees does LA JOLLA PHARMACEUTICAL CO have?
LA JOLLA PHARMACEUTICAL CO (LJPC) currently has 61 employees.
What are the support and resistance levels for LA JOLLA PHARMACEUTICAL CO (LJPC) stock?
LA JOLLA PHARMACEUTICAL CO (LJPC) has a support level at 6.2 and a resistance level at 6.22. Check the full technical report for a detailed analysis of LJPC support and resistance levels.
Is LA JOLLA PHARMACEUTICAL CO (LJPC) expected to grow?
The Revenue of LA JOLLA PHARMACEUTICAL CO (LJPC) is expected to decline by -31.93% in the next year. Check the estimates tab for more information on the LJPC EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy LA JOLLA PHARMACEUTICAL CO (LJPC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LJPC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LJPC, evaluating the profitability, health, valuation and growth aspects
- LA JOLLA PHARMACEUTICAL CO (LJPC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LA JOLLA PHARMACEUTICAL CO (LJPC) Sales and EPS estimates to see what analysts future expectations are.
- LA JOLLA PHARMACEUTICAL CO (LJPC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LA JOLLA PHARMACEUTICAL CO (LJPC) Insider and Institutional Ownership to learn about the owners and their transactions.
- LA JOLLA PHARMACEUTICAL CO (LJPC) Stock Chart to make your own analysis
- LA JOLLA PHARMACEUTICAL CO (LJPC) Latest news and press-releases to stay up to date.
Does LA JOLLA PHARMACEUTICAL CO (LJPC) stock pay dividends?
LJPC does not pay a dividend.
When does LA JOLLA PHARMACEUTICAL CO (LJPC) report earnings?
LA JOLLA PHARMACEUTICAL CO (LJPC) will report earnings on 2022-11-02.
What is the Price/Earnings (PE) ratio of LA JOLLA PHARMACEUTICAL CO (LJPC)?
LA JOLLA PHARMACEUTICAL CO (LJPC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.03).
LJPC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to LJPC. When comparing the yearly performance of all stocks, LJPC is one of the better performing stocks in the market, outperforming 98.66% of all stocks.
LJPC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to LJPC. LJPC has a medium profitability rating, but doesn't score so well on its financial health evaluation.
LJPC Financial Highlights
Over the last trailing twelve months LJPC reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.54% | ||
| ROA | 3.99% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
LJPC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to LJPC. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -92.84% and a revenue growth -31.93% for LJPC